Toferson Fails to Improve Motor Functions in Patients With SOD1 ALS
Toferson alone does not significantly change function in patients with faster progressing SOD1 amyotrophic lateral sclerosis.
Source: neurologyadvisor.com
📰 Rating Scale News
Page 5 - Rating Scale News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rating Scale. Real-time updates on events, politics, business and more.
Treatment with Own Cells Offers Degenerative Disease Hope
Enhancing the number and function of a patient’s own regulatory T-lymphocytes may slow progression of the degenerative disease amyotrophic lateral sclerosis (ALS), an early study suggests.
Source: insideprecisionmedicine.com
Press Release: Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
29.09.2022 - Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 ...
Eva Schaefer Jansen Corentine Driancourt Felix Lauscher Georged Yancopoulos Hannah Kwagh Nathalie Pham
Source: wallstreet-online.de
Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
/PRNewswire/ -- Cellenkos, Inc., a clinical stage biotech company that focuses on developing transformative cellular therapeutics for treatment of inflammatory...
United States Tara Sadeghi Neil Shneider Cellenkos Inc Prnewswire Cellenkos Inc Center At Columbia University
Source: prnewswire.com
FDA Panel Votes in Favor of Fixed-Dose Combination Therapy for ALS
The FDA panel voted in favor of the approval of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of amyotrophic lateral sclerosis.
United States Central Nervous System Drugs Advisory Committee Drug Administration Rating Scale Prescription Drug User Fee Act
Source: empr.com
Amylyx: AdComm Decision Unlikely To Increase ALS Drug Approval
An FDA Advisory Committee will look at fresh data presented by ALS drug developer Amylyx (AMLX) as it attempts to secure accelerated approval. Read more here.
Source: seekingalpha.com
Cureus | Huntington's Disease: A Clinical Review
The Huntington's gene on chromosome 4 has a dominantly inherited CAG trinucleotide repeat expansion, ultimately resulting in Huntington's disease (HD), a completely penetrant neurological condition. The frequency is 10-100 times higher in the population descended from Europe than in East Asia. Through various processes, including impairment of proteostasis, transcription, and cell function, as well as direct toxicity of the mutant protein, mutated huntingtin triggers neuronal malfuncti...
South Africa European Network For Huntington Unified Huntington Disease Rating Scale European Network Unified Huntington Rating Scale
Source: cureus.com
Patients with atopic dermatitis maintain positive outcomes with reduced dupilumab dosages
Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.These findings show that patient-centered dosing regimens can be successful, Lotte S. Spekhorst, MD, of the department of dermatology and allergology and National Expertise Center for Atopic
Lottes Spekhorst Sanofi Genzyme Regeneron Atopic Dermatitis At University Center Utrecht National Expertise Center Rating Scale Atopic Dermatitis
Source: healio.com
Can the Gold Coast Criteria for ALS Help Boost Clinical Trial Participation?
The utilization of the Gold Coast criteria for amyotrophic lateral sclerosis may in the recruitment of patients for clinical trials.
Source: neurologyadvisor.com
Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
France General Eva Schaefer Jansen Corentine Driancourt Felix Lauscher Georged Yancopoulos Vesna Tosic
Source: investegate.co.uk